Nonalcoholic Fatty Liver Disease
568
75
101
292
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
63 trials with published results (11%)
Research Maturity
292 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.6%
26 terminated out of 568 trials
91.8%
+5.3% vs benchmark
9%
51 trials in Phase 3/4
22%
63 of 292 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 292 completed trials
Clinical Trials (568)
Fibrosis Lessens After Metabolic Surgery
The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis in Chinese Children
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
Accuracy of Imaging Techniques in Diagnosing Steatohepatitis and Fibrosis in NAFLD Patients
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Iron Depletion Therapy for Type 2 DM and NAFLD
Effect of Omega-3 PUFA Supplementation in NAFLD Patients
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach
Assessment of Fatty Liver With Thermo-acoustic Device
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Effect of Insulin Lowering on Lipogenesis
NAFLD in Adolescents and Young Adults With PCOS
Phase 2b Study of GSK4532990 in Adults With NASH